melanoma vaccine modified to express hla a2/4-1bb ligand
Vaccineexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01861938)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Melanoma cellsImmunity, active
immunity, active - melanoma cells
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- melanoma vaccine modified to express hla a2/4-1bb ligand
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01861938 | Phase 2/Phase 3 (Phase 3) | Jun 1, 2013 | Hebrew University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hebrew University | Academic/Hospital | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1